By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > GMJ Briefs > Three Critical Gaps Hindering Global Antimicrobial Resistance Response

Three Critical Gaps Hindering Global Antimicrobial Resistance Response

GMJ
Last updated: 28/06/2026 01:36
By
Prof. Giorgi Pkhakadze
Share
1 Min Read
SHARE
1 min read|139 words

As the World Organisation for Animal Health assesses progress toward UN commitments, three key investment gaps emerge as barriers to effective AMR control. First, global funding mechanisms fail to match the scale of political declarations, leaving national action plans underfunded across human, animal, and environmental sectors. Second, the One Health approach—essential for integrated AMR response—requires coordinated investment that currently remains fragmented across independent health systems.

Third, regional infrastructure deficits in low- and middle-income countries perpetuate vulnerability to antimicrobial resistance. Without sustained investment in veterinary services, laboratory diagnostics, and surveillance capabilities, these regions cannot implement evidence-based stewardship programmes. Healthcare stakeholders and policymakers must recognize that closing these gaps demands not just political commitment, but concrete financial allocation and cross-sector collaboration to prevent the projected escalation of AMR-related mortality and economic burden.

Read the full article on GMJ Newsroom.

Was this article helpful?

GMJ Brief · Takeaway

📰 Read the full article: Global Antimicrobial Resistance Investment Falls Short of UN Commitments →

Related reference
  • Iron · Ingredient
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
California Hospital Groups Launch Competing Ballot Initiatives on Healthcare Worker Wages

California's healthcare sector faces competing ballot initiatives from worker unions and hospital…

UK Health Security Agency Publishes New Hantavirus Transmission Parameters for Public Health Response

UK Health Security Agency releases comprehensive guidance on hantavirus human-to-human transmission parameters.…

FDA Approves Sanofi’s Teplizumab for Children with Stage 3 Type 1 Diabetes

FDA approves Sanofi's teplizumab for children with stage 3 type 1 diabetes,…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

MHRA medicines defect notification document for denosumab injection labelling error

MHRA Issues Class 4 Alert for Ponlimsi Denosumab Following Carton Labelling Discrepancy

By
Prof. Giorgi Pkhakadze
22/06/2026

EBOLA OUTBREAK – DRC/UGANDA CROSS-BORDER TRANSMISSION CONFIRMED

By
Prof. Giorgi Pkhakadze
31/05/2026
Medical conference presentation showing obesity drug development data

Next-Generation Triple Hormone Obesity Drugs Advance to Clinical Testing

By
Prof. Giorgi Pkhakadze
20/06/2026
New StudiesResearch Digest

Semaglutide linked to doubled risk of rare vision-threatening eye condition

By
Prof. Giorgi Pkhakadze
26/05/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up